Cancer Research Targets  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fong, L. Y. Y.
Right arrow Articles by Pegg, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fong, L. Y. Y.
Right arrow Articles by Pegg, A. E.
[Cancer Research 63, 3945-3954, July 15, 2003]
© 2003 American Association for Cancer Research


Carcinogenesis

Antizyme Overexpression in Transgenic Mice Reduces Cell Proliferation, Increases Apoptosis, and Reduces N-Nitrosomethylbenzylamine-induced Forestomach Carcinogenesis1

Louise Y. Y. Fong, David J. Feith and Anthony E. Pegg2

Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [L. Y. Y. F.], and Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033 [D. J. F., A. E. P.]


    ABSTRACT
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Antizyme (AZ) is known to be a regulator of polyamine metabolism that inhibits ornithine decarboxylase activity and polyamine transport, thus restricting polyamine levels. Transgenic mice with AZ expression targeted to the basal cell layer of the forestomach epithelium by the keratin 5 promoter were used to investigate whether AZ overexpression inhibited uncontrolled cell proliferation in zinc-deficient (ZD) mice and reduced their susceptibility to forestomach carcinogenesis by N-nitrosomethylbenzylamine (NMBA). Four-week-old keratin 5/AZ and wild-type (Wt) littermates were placed on ZD or zinc-sufficient (ZS) diets to form four groups: ZD:AZ, ZD:Wt, ZS:AZ, and ZS:Wt. After 5 weeks, 27–45 mice in each group were treated twice with NMBA and sacrificed 14 weeks later. Independent of zinc intake, AZ mice had significantly lower forestomach tumor incidence and tumor multiplicity than respective Wt littermates (P < 0.001): 21% of ZD:AZ versus 76% of ZD:Wt mice and 3% of ZS:AZ versus 33% of ZS:Wt mice developed tumors. Spermidine content was reduced in NMBA-treated ZD:AZ forestomachs. Zinc deficiency increased the forestomach cell proliferation in Wt mice, but this effect was blocked by AZ. Conversely, apoptosis was substantially higher in control and NMBA-treated ZD:AZ than respective ZD:Wt forestomachs. The restored ZD:AZ forestomach epithelium displayed strong expression of Bax, a proapoptotic protein, and weak staining of cyclin D1 and its catalytic partner Cdk4, key regulatory proteins controlling G1 to S progression. In contrast, proliferative ZD:Wt forestomach showed strong expression of Bcl-2, an antiapoptotic protein, and overexpression of cyclin D1/Cdk4. Treatment of ZD:Wt mice with {alpha}-difluoromethylornithine, an inhibitor of ornithine decarboxylase, had similar results to AZ in reducing tumor incidence, spermidine content, decreasing cell proliferation, and increasing apoptosis. These results demonstrate that AZ may act as a tumor suppressor gene stimulating apoptosis and restraining cell proliferation, thereby inhibiting forestomach tumor development. Although effects of AZ on functions other than polyamine metabolism are possible, alterations in polyamines are the most likely explanation for the reduction in tumors, supporting the use of strategies to modulate polyamine levels for cancer chemoprevention in individuals at high risk of developing malignancies of the gastrointestinal tract.


    INTRODUCTION
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Polyamines are ubiquitous small basic molecules that play roles in many aspects of cellular physiology. Polyamines are essential for mammalian cell growth and development (1 , 2) , and gene disruptions of ODC3 or S-adenosylmethionine decarboxylase, two key enzymes in polyamine biosynthesis are lethal at early stages of embryonic development (3 , 4) . Many studies have indicated a correlation between polyamine content and neoplastic growth (5) , and the polyamine biosynthetic pathway may be a useful target for the design of cancer chemopreventive and chemotherapeutic agents (6, 7, 8) . The irreversible ODC inhibitor DFMO is currently in clinical trials for chemoprevention of numerous types of cancers (9 , 10) .

ODC (EC 4.1.1.17), which catalyzes the formation of putrescine from ornithine, the first step of cellular polyamine biosynthesis, has been associated with neoplastic growth in many experimental studies. ODC overexpression and increased levels of polyamines alone or in cooperation with other oncogenes can transform cells in vitro (11, 12, 13, 14) . Increased ODC activity is associated with transformation caused by several oncogenes (15, 16, 17, 18) , and ODC transcription is negatively regulated by the Wilms’ tumor suppressor (19) . Transgenic mice overexpressing ODC in the skin are more sensitive to tumor development in response to carcinogens (20) or UV radiation (21) and develop skin tumors without need for tumor promoters (22) .

ODC activity is very highly regulated at multiple levels including transcription, translation and protein degradation (reviewed in Refs. 23, 24, 25 ). A major factor in the regulation of ODC and polyamine homeostasis is AZ (26 , 27) . AZ mRNA contains an internal stop codon preventing the synthesis of the active protein, but a polyamine-dependent +1 frameshifting event allows the translation of AZ mRNA into full-length AZ protein. AZ then binds to the ODC monomer, which prevents formation of the enzymatically active homodimer and, therefore, reduces ODC activity. More critically, the binding of AZ stimulates the degradation of ODC by the 26S proteasome in an ATP-dependent but ubiquitin-independent manner. Mammalian cells also possess a highly inducible polyamine transport system, which is activated when internal polyamine content falls. This uptake system is also inhibited by AZ, and there is some evidence that AZ may also stimulate polyamine excretion (27) . Thus, AZ reduces polyamine content and contributes to polyamine homeostasis through multiple mechanisms. Recent studies have indicated that there may be a family of AZ molecules in addition to that first discovered, which is now termed AZ-1 (27 , 28) . The function of these multiple forms of AZ is not yet known.

Transgenic mice in which AZ-1 is expressed from the bovine K5 and K6 promoter elements have been derived (29) . The AZ-1 cDNA construct used had a single nucleotide deletion (T205) to remove the requirement for polyamine-stimulated frameshifting in the translation of the mRNA. There are two potential start codons in the AZ-1 cDNA, and both are present in the transgene, but Western blots of epidermal extracts indicated that the second site was used preferentially in vivo (29) . Both K5/AZ and K6/AZ transgenic mice developed normally and were phenotypically indistinguishable from Wt littermates. However, the transgenic AZ expression blocked the increase in skin ODC induced by tumor promoters, and reduced epidermal and dermal polyamine content, particularly spermidine. Carcinogenesis studies using a two stage protocol with initiation with 7,12-dimethylbenz(a)anthracene and treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate showed that two founder lines of K6/AZ mice had a delay in tumor onset and a substantial reduction in tumor multiplicity compared with normal littermates. K5/AZ mice also developed fewer papillomas than littermate controls, and combination of these lines to produce K5/AZ-K6/AZ double transgenic animals yielded an additive decrease in tumor multiplicity (29) . These studies were carried out on a mixed B6D2 genetic background, but the results were confirmed in a defined genetic background after the transgenic lines were backcrossed onto the carcinogenesis-resistant C57BL/6J inbred strain as well as the sensitive DBA/2J strain (30) . There was a greater effect with the K6/AZ lines, which is consistent with the more complete inhibition of ODC activity in K6/AZ compared with K5/AZ mice in response to 12-O-tetradecanoylphorbol-13-acetate application.

These results suggest that AZ acts as a tumor suppressor and that the transgenic mice expressing AZ can be used to investigate which pathways of carcinogenesis have an essential increase in polyamine metabolism as a contributory factor. AZ expression from the K5 promoter is not limited to the skin but may occur in other epithelial cells. Numerous studies have demonstrated that the K5 promoter can drive transgene expression in other stratified epithelia in addition to skin, such as the esophagus and forestomach (31, 32, 33, 34) , thymus (31 , 32) , and prostate (35) .

Therefore, we have studied the incidence of tumors in K5/AZ mice after treatment with NMBA. This carcinogen is known to produce esophageal cancer in rats, and tumor development is accelerated by exposure to a ZD diet that induces proliferation in target cells (31 , 37) . Treatment of rats with NMBA and a ZD diet provides an important model system, which reproduces many aspects of the development of esophageal squamous cell carcinoma in humans in high risk areas such as northern China and Iran (38 , 39) . Mice also develop tumors readily in response to NMBA and a ZD diet (40 , 41) . However, in mice there is a higher incidence of tumors in the forestomach, which is considered to be a dilation of the lower esophagus (42) , than in esophagus. A loss of p53 increased the sensitivity of ZD mice to NMBA-induced esophageal/forestomach carcinogenesis (41) . The rapid rate of tumor induction/progression in ZD:p53-/- mice was accompanied by an increase in the rate of cell proliferation and a decrease in apoptosis.

The studies reported here show that AZ expression has the opposite effect to zinc deficiency and lack of p53 in that it stimulates apoptosis, restrains cell proliferation, and inhibits forestomach tumor development. These results are supported by studies in which DFMO was tested and found to also reduce tumor development after NMBA treatment. These findings emphasize the potential value of using drugs targeting the polyamine metabolic pathway as cancer chemopreventive agents.


    MATERIALS AND METHODS
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Transgenic Mice.
This study was approved by the Thomas Jefferson University Institutional Animal Care and Use Committee and conducted under NIH guidelines. The generation of K5-AZ transgenic mice was described previously (29) . All of the animals used for the experiments were from the fifth or sixth backcross generation to C57BL/6J mice; therefore, >98% of their genes are derived from this inbred strain. Breeding of transgenic males from a single founder line to C57BL/6J females (The Jackson Laboratory, Bar Harbor, ME) generated a total of 130 AZ transgenic mice and 136 Wt littermates (with about equal number of males and females) for the forestomach tumorigenesis study. The AZ and Wt offspring were differentiated by genotyping of tail DNA using a PCR-based method (29) .

Chemicals and Diets.
NMBA was purchased from Ash Stevens, Inc. (Detroit, MI). Custom-formulated, egg white-based ZD and ZS diets containing 1.5 and 75 ppm zinc, respectively, were prepared by Teklad (Madison, WI). The ZD diet is nutritionally complete and is identical to ZS diet except for the concentration of elemental zinc (36) .

Zinc Determination.
The testes were removed from male and hair from female animals at necropsy. Samples of testis or hair were dried to constant weight at 90°C and ashed in a furnace. Ashed samples were dissolved in 0.1 N HCl and the zinc content determined by atomic spectrometry as described (36) . Zinc content was expressed as µg/g dry weight of testis or hair. Overt signs of zinc deficiency that are well-described for ZD rats (36) , including foci of alopecia, skin lesions, and retarded growth, were not evident in ZD:Wt or ZD:AZ mice, which had similar body weights at end point (Table 1)Citation . However, zinc content in the testis (male) and hair (female) was significantly lower in ZD than ZS mice, regardless of genotype and other treatment (P < 0.001; Table 1Citation ).


View this table:
[in this window]
[in a new window]

 
Table 1 Effect of a zinc-deficient diet on zinc content and body weight

Four-week-old mice were fed ZD or ZS diet for 5 weeks, and were then given intragastrically, two or four NMBA doses, twice per week. The animals were sacrificed 14 weeks later. Values are shown as the mean ± SD. Zinc content (2x NMBA, 4x NMBA): testis (n = 5–16), hair (n = 5–18), ZD:Wt versus ZS:Wt, ZD:AZ versus ZS:AZ, P < 0.001. All statistical tests were two-sided.

 
Forestomach Tumorigenesis Experiment in AZ Transgenic Mice.
The experiment was conducted in batches when the mice became available from our breeding colonies. Four-week-old mice (AZ male, 13.1 ± 1.5 g and female, 12.3 ± 1.4 g; Wt male, 13.0 ± 1.9 g and female, 12.6 ± 1.7 g) were housed 3–5 to a polycarbonate cage with a wire stainless steel floor. They were given free access to deionized drinking water. The mice were randomized into two dietary groups and were fed ad libitum a ZD or control ZS diet, forming four experimental groups: ZD:Wt, ZD:AZ, ZS:Wt, and ZS:AZ. After 5 weeks, 10 mice from each group (control mice) were sacrificed to determine the extent of cell proliferation and apoptosis in the forestomach. The remaining animals (27–45 mice/group and 15–29 mice/group in 2x NMBA and 4x NMBA studies, respectively) were treated with two or four intragastric doses of NMBA at 2 mg/kg body weight, twice weekly. NMBA-treated animals continued on their respective diet and were sacrificed 14 weeks after the first carcinogen treatment for end point tumor incidence analysis.

Effect of DFMO on Forestomach Tumorigenesis in C57BL/6 Mice.
To evaluate the effect of DFMO in ZD mice, 75 weanling male C57BL/6 mice (11.7 ± 1.3 g) were purchased from Taconic Laboratory (Germantown, NY). The animals were randomly divided into two dietary groups as described above. To determine the extent of cell proliferation before NMBA dosing (0 h), 5 ZD and 5 ZS mice were killed after 5 weeks of experimental diet. The remaining mice received two intragastric doses of NMBA at 2 mg/kg body weight per week. After the first dose, the animals were divided into four groups (14–20 mice/group): ZD/DFMO-; ZD/DFMO+; ZS/DFMO-, and ZS/DFMO+. DFMO- mice remained on deionized water, whereas DFMO+ animals were given deionized water containing 1% DFMO. All of the mice continued on their respective diet. After 2 weeks, 5 mice from each group were killed to determine the effect of DFMO on forestomach cell proliferation. The remaining 45 mice were sacrificed 12 weeks after the first NMBA dose for tumor incidence analysis.

Tumor Analysis.
After anesthetization with isoflurane (Ohmeda Inc., Madison, WI), the mice were sacrificed and subjected to complete necropsies. Whole stomachs were excised and opened longitudinally. Tumors >0.5 mm in diameter in the forestomach were mapped and counted. Whole forestomachs were fixed in buffered formalin and embedded in paraffin. The forestomach was cut into 4–6 strips, across the SCJ. Then, 4-µm thick cross-sections were cut. Typically, there were 4 to 6 sections per slide, representing the entire forestomach/SCJ. Sections were either stained with H&E for histopathology or left unstained for immunohistochemical studies.

Polyamine Analysis.
At necropsy, a small strip of forestomach epithelium was cut and snap-frozen in liquid nitrogen. The samples were stored at -80°C until polyamine analysis. Each sample represented three pooled strips from mice of the same treatment group for the 2xNMBA experiment or a single tissue sample for the DFMO experiment. Polyamine content in forestomach was determined after separation by ion-pair reversed-phase high-pressure liquid chromatography using fluorescence detection after postcolumn derivatization with o-phthalaldehyde as described previously (43) and normalized to tissue wet weight (in grams). Normalization to mg protein/sample yielded similar results.

Cell Proliferation Determination by PCNA Immunohistochemistry.
Monoclonal mouse anti-PCNA (Santa Cruz Biotech., Santa Cruz, CA) was used at 1:500 dilution, followed by incubations with biotinylated goat antimouse antibody and streptavidin horseradish peroxidase. PCNA was localized by a final incubation with 3-amino-9-ethylcarbazole-substrate-chromogen system (Dako Corp., Carpinteria, CA), and a light hematoxylin counterstain. Cells with red reaction product in the nucleus were considered positive for the presence of PCNA.

Apoptosis Analysis.
Apoptosis was assessed by the TUNEL method and by morphological characterization of cells in H&E stained sections.

TUNEL Assay.
The 3'-OH end labeling of DNA in tissue sections was performed with an ApopTaq in situ peroxidase detection kit (Serologicals Corp., Norcross, GA). Sections were deparaffinized, rehydrated in a graded alcohol series, and incubated with proteinase K (20 µg/ml, 37°C for 10 min). Endogenous peroxidase in the sections was inhibited with 3% hydrogen peroxide, and slides were incubated (37°C for l h) with terminal deoxynucleotidyl transferase to catalyze the addition of digoxigenin-labeled nucleotides to the 3'-OH ends of fragmented DNA. Next, slides were incubated with horseradish peroxidase-conjugated antidigoxigenin antibodies, and DNA fragmentation was detected by staining with DAB. Finally, sections were counterstained with methyl green. Sections from rat mammary gland (Serologicals Corp.), in which extensive apoptosis occurs, served as a positive control. Negative controls omitted terminal deoxynucleotidyl transferase.

Morphological Criteria.
The incidence of apoptosis was measured on good-quality sections stained with H&E. The morphology of apoptotic cells depends on their stage in the process. Apoptotic morphologies include diffuse cytoplasmic staining with only minimal nuclear condensation, distinct apoptotic bodies resulting from nuclear disintegration, or dense staining nuclei with normal nuclear structure (44) . All three of the forms were considered to be equivalent, and the AI, expressed as a percentage, was calculated by dividing the number of apoptotic cells by the total number of cells in the tissue section.

K5 and AZ Immunohistochemistry.
Antiserum to AZ was produced in rabbits immunized with a purified recombinant polyhistidine-tagged AZ fusion protein and then purified using an AZ-affinity column as described previously (29) . After deparaffinization and rehydration in graded alcohols, forestomach sections were heated in citrate buffer [0.01 M (pH 6.0)] in a microwave oven (88–95°C; 3 x 5 min) before nonspecific binding sites were blocked with goat serum. Sections were incubated overnight at 37°C in a humidified chamber with rabbit anti-AZ antiserum at 1:200 dilution followed by incubation with biotinylated goat antirabbit antibody serum (1:500 dilution). Slides were then incubated with streptavidin horseradish peroxidase (1:1000 dilution). Cytoplasmic expression of AZ was localized by a final incubation with DAB and a light hematoxylin counterstain.

K5 was detected using a polyclonal antibody against mouse K5 (Covance Research Products, Berkeley, CA) at a 1:500 dilution and visualized with the Vectastain Elite ABC kit with DAB chromagen (Vector Laboratories, Burlingame, CA).

Bax and Bcl-2 Immunohistochemistry.
To detect Bax and Bcl-2, forestomach sections were incubated overnight at 37°C in a humidified chamber with a rabbit anti-Bcl-2 polyclonal antiserum (Santa Cruz) at a 1:400 dilution, or with a rabbit anti-Bax polyclonal antiserum (Santa Cruz) at a 1:200 dilution, followed by incubation with a biotinylated goat antirabbit antibody serum. Cytoplasmic Bcl-2 and Bax expression was visualized with DAB.

Cyclin D1 and Cdk4 Immunohistochemistry.
To detect cyclin D1 and Cdk4, forestomach sections were incubated as described above with a rabbit anticyclin D1 polyclonal antiserum (Lab Vision Corp., Fremont, CA) at a 1:100 dilution or with a rabbit anti-Cdk4 polyclonal antiserum (Santa Cruz) at a 1:100 dilution, followed by incubation with a biotinylated goat antirabbit antibody serum. Nuclear cyclin D1 and Cdk4 expression was visualized with DAB.

Statistical Analysis.
Tumor incidence differences were analyzed by two-tailed Fisher’s exact test, and data on cell proliferation and testis zinc level were analyzed by one-way ANOVA with the SAS statistical computer program as described (41) . All of the statistical tests were two-sided and were considered statistically significant at P < 0.05.


    RESULTS
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Effect of AZ Expression on Forestomach Carcinogenesis.
Fourteen weeks after two NMBA doses, ZD:Wt mice invariably showed a thickened and shrunken forestomach, with a 76% and 56% tumor incidence in the forestomach and SCJ, respectively, and a forestomach tumor multiplicity of 2.6 (Fig. 1, A and C)Citation . There was a large and highly significant reduction in tumor incidence in ZD:AZ mice (21% forestomach and 18% SCJ) and in tumor multiplicity (0.4). Although the overall tumor incidence was lower in ZS:Wt mice (which is consistent with previous results in C57BL/6 mice; Refs. 40 , 41 ) ZS:AZ mice, relative to their ZS:Wt counterparts, also had significantly lower tumor incidence in the forestomach (3% versus 33%) and SCJ (0% versus 30%; Fig. 1ACitation ). Similar results were obtained in a second experiment in which the mice were given four doses of NMBA and sacrificed 14 weeks later for tumor incidence analysis (Fig. 1, B and D)Citation . Notably, only 15% of ZD:AZ mice had forestomach tumors versus 80% of their ZD:Wt counterparts, and tumor multiplicity was 0.5 versus 3.8. In the ZS mice, AZ expression caused a drop in forestomach tumors from 41% to 12%. Tumors at the SCJ were also reduced by AZ in both ZD and ZS mice. Esophageal tumors were not detected in ZD:Wt mice probably because the animals in the present study were exposed to fewer NMBA doses than in the previous study (40) .



View larger version (44K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 1. Reduction of NMBA-induced forestomach carcinogenesis in AZ transgenic mice. Four-week-old mice were fed ZD or ZS diet for 5 weeks, and were then given two (A and C) or four (B and D) NMBA doses, intragastrically twice per week. The animals were sacrificed 14 weeks later. A and B, show the percentage of tumor incidence in the forestomach and SCJ with the glandular stomach. The number of animals with tumors and the total number of mice is shown above each bar. C and D show the tumor multiplicity of forestomach tumors and the SE. Statistical analysis of significance of percentage of tumor incidence: 2x NMBA, ZD:AZ versus ZD:Wt, forestomach and SCJ, P < 0.001; ZS:AZ versus ZS:Wt, forestomach, P = 0.003 and SCJ, P < 0.001; ZD:Wt versus ZS:Wt, forestomach, P < 0.001 and SCJ, P = 0.05; ZD:AZ versus ZS:AZ, forestomach, P = 0.032 and SCJ, P = 0.013; 4x NMBA, ZD:AZ versus ZD:Wt, forestomach, P < 0.001 and SCJ, P = 0.004; ZS:AZ versus ZS:Wt, forestomach, P = 0.048; ZD:Wt versus ZS:Wt, forestomach, P = 0.025 and SCJ, P = 0.009. Statistical analysis of significance of tumors/forestomach: 2x NMBA, ZD:AZ versus ZD:Wt and ZD:Wt versus ZS:Wt, P < 0.001; 4x NMBA, ZD:AZ versus ZD:Wt; and ZD:Wt versus ZS:Wt, P < 0.001. All statistical tests were two-sided.

 
Tumor-bearing ZD:Wt mice regularly displayed large, fused forestomach tumors (Fig. 2A)Citation or large, solitary tumors (Fig. 2B)Citation . On the contrary, ~80% of ZD:AZ mice showed a tumor-free forestomach that was mostly large and thin (Fig. 2C)Citation or slightly thickened at the SCJ (Fig. 2D)Citation . The results shown in Fig. 2Citation were obtained with mice given two doses of NMBA but similar results (data not shown) were obtained after four doses of the carcinogen.



View larger version (130K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 2. Macroscopic appearance of forestomachs of ZD:Wt and ZD:AZ mice 14 weeks after two doses of NMBA. Representative pictures of individual mice are shown. ZD:Wt forestomachs display large, fused tumors (A), and large solitary tumors (B), whereas ZD:AZ forestomachs show a tumor-free, thin forestomach and SCJ (C), or exhibit a tumor-free forestomach with thickened SCJ (D). Gross photographs, x5.3.

 
The expression pattern of AZ in the forestomach epithelium of K5/AZ transgenic mice was determined both indirectly by K5 immunostaining and directly by AZ immunostaining. Endogenous K5 was readily visualized in the forestomach of both AZ and control mice by immunohistochemistry. K5 staining was strong and uniform throughout the basal cell layer of the forestomach and within areas of hyperproliferation. The staining was weak and patchy within the suprabasal layer. These patterns of K5 staining were consistent independent of diet, genotype, or carcinogen treatment (data not shown). These results are consistent with previous studies showing that the K5 promoter is active in the forestomach (31, 32, 33, 34) . AZ expression was visualized using immunohistochemical staining with an antiserum to purified recombinant rat AZ. This revealed higher levels of AZ expression in the cytoplasm of forestomach epithelial cells from K5/AZ mice relative to control animals (Fig. 3)Citation .



View larger version (180K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 3. Immunohistochemical detection of AZ in ZS:AZ forestomach. A forestomach section from an NMBA-treated ZS:AZ mouse displayed moderately strong cytoplasmic staining of AZ in many cells (representative cells shown by arrows) in the proliferative forestomach epithelium (B) versus forestomach from an NMBA-treated ZS:wt mouse showing lack of AZ expression (A). The bars represent 50 µm.

 
Reduced Cell Proliferation in Control ZD:AZ Mice.
Visual inspection of control mice after 5 weeks of the ZD diet typically showed a thickened forestomach and SCJ in ZD:Wt mice but a large and thin forestomach in ZD:AZ animals, suggesting nutritional zinc deprivation did not have an effect on forestomach cell proliferation in the latter. Histopathologic examination of control forestomach sections showed that the level of cell proliferation was highest in ZD:Wt mice, followed by ZS:Wt, and then ZD:AZ >= ZS:AZ. Although AZ overexpression reduced cell proliferation in both ZD and ZS forestomach, its effect was more dramatic in ZD mice, and photomicrographs are presented of ZD tissue sections (Fig. 4)Citation . Relative to ZS:Wt forestomach that exhibited occasional and mild proliferation (data not shown), ZD:Wt forestomach regularly displayed a proliferative epithelium with small upward and downward focal hyperplastic lesions (Fig. 4A)Citation , showing many PCNA-positive nuclei (Fig. 4E)Citation , and overexpression of Cdk4 (Fig. 4I)Citation and cyclin D1 (Fig. 4M)Citation in these lesions. PCNA is an endogenous cell proliferation marker; cyclin D1 and its catalytic partner, Cdk4, are major G1-S regulatory proteins (45) . These results are consistent with previous data that demonstrated that proliferative esophagi from untreated ZD rats had altered expression profiles for genes that control G1-S progression (43) . In contrast, AZ mice on a ZD diet typically showed a thin forestomach epithelium of 2–5 cells thick (Fig. 4B)Citation , with PCNA-positive nuclei mainly in the basal cell layer (Fig. 4F)Citation , and weak and sporadic expression of Cdk4 (Fig. 4J)Citation and cyclin D1 (Fig. 4N)Citation . Thus, AZ overexpression in ZD mice restrains Cdk4/cyclin D1 expression and inhibits cell proliferation in the forestomach.



View larger version (92K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 4. Cell proliferation in control and NMBA-treated ZD:AZ and ZD:Wt forestomachs. H&E staining (A–D), immunohistochemistry for PCNA (E–H), Cdk4 (I–L), and cyclin D1 (M–P) were used. Representative pictures of individual mice are shown. A, B, E, F, I, J, M, and N show results from mice fed ZD diet for 5 weeks with no NMBA treatment. ZD:Wt mice showed: a hyperplastic epithelium with focal hyperplastic lesions (A) displaying numerous PCNA-positive nuclei (3-amino-9-ethylcarbazole, red) in S phase, and G1-S/G2 phase (E); strong nuclear expression of Cdk4 (I, DAB, brown); and strong nuclear staining of cyclin D1 (DAB, brown) in basal cells and focal hyperplastic lesions (M). Conversely, ZD:AZ mice showed: a thin epithelium (B) with PCNA-positive cells mainly in the basal cell layer (F); moderate expression of Cdk4 in basal cells (J); and sporadic expression of cyclin D1 in basal cells (N). C, D, G, H, K, L, O, and P show results from mice fed ZD diet, treated with two NMBA doses, and sacrificed 14 weeks later. Sections from ZD:Wt mice showed: a dysplastic epithelium with deep focal hyperplastic lesions (C), abundant PCNA-positive nuclei (G), overexpression of cyclin D1 (O) in these lesions, and overexpression of Cdk4 in a dysplastic epithelium (K). Forestomach sections from ZD:AZ mice showed: a thin epithelium displaying many apoptotic cells (D and inset); infrequent PCNA-positive nuclei mainly in the basal cell layer (H); a few strongly stained Cdk4-positive (L); and cyclin D1-positive (P) nuclei, mainly in basal cells. Bars: 100 µm for A–C and G; 50 µm for D–F and H–P; 25 µm for the inset.

 
Quantitative PCNA-immunohistochemistry showed that dietary zinc deficiency induced a high rate of cell proliferation in the forestomach of Wt mice (Fig. 5ACitation , Expt. 1), a result consistent with previous studies in rats (46) and mice (40) . The PCNA-LI, a measure of cellular proliferation, was significantly higher in ZD:Wt than ZS:Wt forestomach. Overexpression of AZ in ZD mice counteracted the effect of zinc deficiency on cell proliferation and brought about a significantly reduced LI compared with ZD:Wt forestomach. Likewise, LI was significantly lower in ZS:AZ than ZS:Wt forestomach (Fig. 5ACitation , Expt. 1).



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 5. Rates of cell proliferation (A) and apoptosis (B) in forestomach. Results are shown from three experiments. Experiment 1 shows data from control AZ transgenic and Wt littermates fed a ZD or ZS diet for 5 weeks. Experiment 2 shows data from ZD mice treated with 2 doses of NMBA as described in the legend to Fig. 1Citation . Experiment 3 shows results from ZD mice treated with two doses of NMBA with and without DFMO as described in the legend to Fig. 8Citation . The PCNA-LI (%; A) is calculated by dividing the number of respective labeled cells in S phase by the total number of cells/cross-section of tissue, and the result is expressed as a percentage. The AI (%; B) is calculated by dividing the number of apoptotic cells by the total number of cells/cross-section of tissue, and the result is expressed as a percentage. Statistical analysis was two sided with 7–11 animals in each group; bars, ±SD. Statistical analysis for LI in experiment 1: ZD:Wt versus ZS:Wt, P < 0.001; ZD:AZ versus ZD:Wt, P < 0.001; ZS:AZ versus ZS:Wt, P < 0.001; ZD:AZ versus ZS:AZ, NS. Statistical analysis for AI in experiment 1: ZD:Wt versus ZS:Wt, P < 0.001; ZD:AZ versus ZD:Wt, P < 0.001; ZS:AZ versus ZS:Wt. P < 0.05; ZD:AZ versus ZS:AZ, P < 0.001. Statistical analysis for experiment 2: ZD:AZ versus ZD:Wt, P < 0.001 (n = 11) for both LI and AI. Statistical analysis for experiment 3: ZD:DFMO+ versus ZD:DFMO-, P < 0.001 (n = 11) for both LI and AI.

 
Increased Apoptosis in Control ZD:AZ Mice.
AIs were determined in high quality H&E-stained forestomach sections of control ZD and ZS mice of both AZ and Wt genotypes (Fig. 5BCitation , Expt. 1). Zinc deficiency produced a significant decrease in the AI of Wt mice. Expression of AZ increased the AI, which was significantly higher in ZD:AZ compared with ZD:Wt forestomach and in ZS:AZ compared with ZS:Wt forestomach. In addition, TUNEL analysis (Fig. 6)Citation showed frequent occurrence of darkly stained TUNEL-positive nuclei in the restored and sometimes still proliferative forestomach epithelium of ZD:AZ mice compared with ZD:Wt forestomach, which had only occasional incidences of apoptotic cells (Fig. 6Citation , B versus A).



View larger version (84K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 6. Apoptosis in control and NMBA-treated ZD:AZ and ZD:Wt forestomachs. TUNEL analysis (A–D), immunohistochemistry for Bax (E–H), and Bcl-2 (I–L) were used. Representative pictures of individual mice are shown. A, B, E, F, I, and J show results from mice fed ZD diet for 5 weeks with no NMBA treatment. ZD:Wt mice forestomachs showed: lack of strongly stained TUNEL-positive apoptotic nuclei (A); very weak and diffuse cytoplasmic expression of Bax (E); and strong cytoplasmic staining of Bcl-2 in basal cells and focal hyperplastic lesion (I). In contrast, ZD:AZ forestomachs showed: strongly stained TUNEL-positive nuclei in the basal cell layer of restored epithelium (B); with overexpression of Bax in a proliferative location (F); and weak expression of Bcl-2 in basal cells (J). C, D, G, H, K, and L show results from mice fed ZD diet, treated with two NMBA doses, and sacrificed 14 weeks later. Sections of ZD:Wt forestomachs showed: the occurrence of a single TUNEL-positive nucleus in deep focal hyperplastic lesions; scattered expression of Bax (G); and intense expression of Bcl-2 in these lesions (K). In contrast, ZD:AZ forestomachs showed: numerous darkly stained TUNEL-positive nuclei in a restored epithelium (D); intense cytoplasmic staining of Bax in a mildly proliferative epithelium (H and inset); and moderate expression of Bcl-2 in basal cells (L). Bars, 50 µm for A–L, and 25 µm for the inset.

 
Fig. 6Citation also shows immunohistochemical staining for Bax, a proapoptotic protein, and Bcl-2, an antiapoptotic protein in forestomach sections. This revealed diffuse and weak staining of Bax in ZD:Wt sections (Fig. 6E)Citation but strong staining in ZD:AZ epithelium (Fig. 6F)Citation . On the other hand, Bcl-2 expression was typically strong in the basal and proliferative areas of ZD:Wt (Fig. 6I)Citation forestomach but weak and infrequent in ZD:AZ epithelium (Fig. 6J)Citation .

Cell Proliferation and Apoptosis in NMBA-treated ZD:AZ Mice.
Detailed cell proliferation and apoptosis results are presented in Figs. 4Citation 5Citation 6Citation for treated ZD:AZ and ZD:Wt mice of the two NMBA dose experiment. At 14 weeks, the ZD:AZ forestomach demonstrated significantly lower LI than their ZD:Wt counterparts (Fig. 5ACitation , Expt. 2) a result consistent with those from respective control groups (Fig. 5ACitation , Expt. 1). Typically, ZD:Wt forestomach displayed numerous PCNA-positive nuclei in areas of hyperplasia, dysplasia, and papilloma, whereas ZD:AZ forestomach showed a few PCNA-positive nuclei mainly in the basal cell layer (Fig. 4Citation , G versus H). In addition, ZD:Wt forestomach lesions exhibited overexpression of Cdk4 (Fig. 4K)Citation and cyclin D1 (Fig. 4O)Citation in these lesions, whereas ZD:AZ forestomach showed moderate expression of these two G1 to S regulatory proteins, mostly in basal cells (Fig. 4, L and P)Citation .

On the other hand, the AI was significantly higher in ZD:AZ than ZD:Wt forestomachs (Fig. 5BCitation , Expt. 2). These data are in line with those from respective control groups (Fig. 5BCitation , Expt. 1). H&E-stained and TUNEL-stained forestomach sections from ZD:AZ mice displayed frequent occurrence of apoptotic cells (Fig. 4DCitation ; Fig. 6DCitation ), whereas those from ZD:Wt animals showed only isolated occurrences (Fig. 4CCitation ; Fig. 6CCitation ). Bax expression was intense and abundant in ZD:AZ forestomach (Fig. 6H)Citation but moderate and sparse in ZD:Wt forestomach (Fig. 6G)Citation . Conversely, Bcl-2 expression was moderate and mostly in the basal cells of ZD:AZ forestomach (Fig. 6L)Citation but strong and abundant in ZD:Wt forestomach lesions (Fig. 6K)Citation .

Effect of AZ Expression on Polyamine Levels in the Mouse Forestomach.
The most probable explanation for the striking effect of transgenic AZ expression on tumor incidence, cell proliferation, and apoptosis described above is that polyamine levels influence these processes, and that the inhibitory effects of AZ on ODC and polyamine transport alter polyamine levels. Direct assessment of alterations in ODC levels were not possible, because ODC activity measurements could not be made reliably on tissue samples because of the small amount of tissue available and the limited sensitivity of these assays. Except for putrescine, which was at the limit of detection, polyamine levels could be measured accurately in the forestomach tissue. In samples collected at 14 weeks after treatment with two doses of NMBA, there was a statistically significant reduction in the spermidine content of the ZD:AZ group compared with ZD:Wt (Fig. 7)Citation . However, the differences were small, and spermidine values were not statistically significantly decreased in the comparison of the ZS:AZ and ZS:Wt groups. A probable explanation for this is that the relevant epithelial cell population makes up only a small proportion of the tissue used for this analysis because the underlying connective tissue and muscle layers are also retained in this analysis. Therefore, additional study of the possible role of polyamines in cell proliferation and forestomach carcinogenesis in ZD mice was carried out using the ODC inhibitor DFMO.



View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 7. Polyamine content of forestomach of NMBA-treated ZD and ZS mice. Four-week-old mice (AZ or Wt) were fed ZD or ZS diet for 5 weeks, and were then given two intragastric doses of NMBA and sacrificed 14 weeks later. Forestomach samples were taken and polyamine content analyzed. Results are shown for putrescine, spermidine, and spermine. The number of samples analyzed was: ZD:Wt, 11; ZD:AZ, 11; ZS:Wt, 5; and ZS:AZ, 10. Because of the small amount of tissue available, each sample contained tissues pooled from 3 mice; bars, ± SD. Statistical analysis was two sided, and the only values that were significantly different were spermidine content for ZD:Wt versus ZD:AZ; P < 0.01.

 
Effect of DFMO on Polyamine Levels, Tumor Incidence, and Cell Proliferation in Forestomach of ZD Mice.
ZD C57BL/6 mice were treated with the two-dose NMBA protocol, and half of the animals in each group received 1% DFMO in the drinking water starting after the first NMBA dose. DFMO treatment did lead to a small reduction in body weight but did not affect the zinc deficiency (Compare Table 2Citation with Table 1Citation ). Table 2Citation shows that 87% of male C57BL/6 mice developed forestomach tumors at week 12 after two doses of NMBA, with a tumor multiplicity of 3.7. ZD mice that were switched to drinking water containing 1% DFMO after 5 weeks of a deficient diet exhibited a greatly reduced tumor incidence of 9%, with a lower tumor multiplicity of 0.2 (Table 2)Citation . The spermidine content of the forestomach was reduced significantly by DFMO to about the same extent as that by AZ (compare Table 2Citation and Fig. 7Citation ). DFMO treatment also reduced the tumor incidence and the spermidine content in ZS mice treated with the two-dose NMBA protocol, although the tumor incidence in the ZS mice not receiving DFMO was considerably lower than in ZD mice (results not shown).


View this table:
[in this window]
[in a new window]

 
Table 2 Reduction of NMBA-induced forestomach carcinogenesis by DFMO in C57BL/6 mice on a ZD diet

Male weanling C57BL/6 mice were fed ZD diet for 5 weeks. The mice were then given two doses of NMBA. After the first dose, DFMO+ groups received 1% DFMO in the drinking water. All mice were sacrificed at week 12. Statistical analysis of significance of % tumor incidence for both forestomach and squamocolumnar junction and tumor multiplicity, DFMO+ versus DFMO-, P < 0.001. Statistical analysis of significance of polyamine content, spermidine: DFMO+ versus DFMO-, P = 0.003. Statistical analysis of significance of body weight: DFMO+ versus DFMO-, P < 0.01. All statistical tests were two-sided.

 
DFMO, administered after the establishment of increased cell proliferation by nutritional zinc deficiency, reversed the increased cell proliferation in the mouse forestomach (Fig. 8)Citation . After 5 weeks of the ZD diet, the forestomach typically displayed a proliferative epithelium with many PCNA-positive nuclei in small focal hyperplastic up- and down-growths (Fig. 8A)Citation . At week 2 after NMBA treatment, there was an expansion in focal hyperplastic lesions that was accompanied by an increase in PCNA-positive S phase cells (Fig. 8B)Citation . At week 12, PCNA-positive cells were found in areas of hyperplasia, dysplasia, focal hyperplastic lesions, and papilloma (Fig. 8C)Citation . In contrast, when DFMO was given starting at the time of the first NMBA treatment, within 2 weeks after NMBA and DFMO administration, a restored forestomach epithelium with a thickness of 2–6 cells was in place, with PCNA-positive nuclei mainly in the basal cell layer (Fig. 8D)Citation . At week 12, the forestomach in the DFMO-treated group was mostly 2–5 cells thick with a few PCNA-positive nuclei, mainly in basal cells (Fig. 8E)Citation . Quantitative PCNA immunohistochemistry demonstrated a significantly lower PCNA-LI in ZD/DFMO+ than ZD/DFMO- forestomachs at week 12 (Fig. 5ACitation , Expt. 3). In addition, these ZD/DFMO+ forestomachs showed a significantly higher AI (%) than the corresponding ZD/DFMO- forestomach (Fig. 5BCitation , Expt. 3).



View larger version (109K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 8. Reversal of pre-established cell proliferation in forestomach of NMBA-treated ZD mice by DFMO. Mice were treated for 5 weeks with the ZD diet and then with two doses of NMBA as in the legend to Fig. 1Citation . Half of the mice received DFMO in the drinking water (DFMO+) and the others did not (DFMO-). PCNA immunohistochemistry with counterstaining with hematoxylin was then carried out on forestomach samples. A–C show representative results for ZD; DFMO- mice: at 0 h (5 weeks after ZD diet), at 2 weeks (B), and 12 weeks (C) after two NMBA doses. Numerous PNCA-positive regions in small upward and downward focal hyperplastic lesions are seen at 0 h (A) with abundant PCNA-positive nuclei in expanded focal hyperplastic lesions at 2 weeks (B) and papillomas at 12 weeks (C). D and E show results for DFMO+ mice at 2 weeks (D) and 12 weeks (E). These show a restored epithelium of 2–3 cells thick with PCNA-positive nuclei, mainly in the basal cell layer (D and E). Bars, 100 µm.

 

    DISCUSSION
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The moderate expression of AZ from the K5 promoter has no obvious deleterious effects in these transgenic mice. Detailed examination has only been carried out in the skin (29 , 30) and in the esophagus/forestomach, but no significant effects were seen in the absence of treatment with carcinogens or tumor promoters. The transgenic mice have no obvious phenotype and live a normal life span. However, the results provided here and those in which skin tumor development was examined (29 , 30) show that they are highly resistant to tumor development after treatment with regimes that initiate and promote carcinogenesis.

It is firmly established that AZ is a regulator of polyamine content. There have been suggestions that AZ may cause a reduction in the content of other proteins including cyclin D1, cdk4, Smad1, and SNIP1 (27 , 47) . These reports are highly preliminary and have not yet been confirmed. However, we certainly cannot at present rule out the possibility that the tumor-suppressive effects of AZ are mediated or enhanced via effects on these pathways or others.

It is most probable that the cancer preventative effect is attributable to a reduction in cellular polyamine content. Although there was only a small decline in spermidine in the treated AZ mice compared with treated controls (Fig. 7)Citation , this reduction was similar to that produced by the administration of DFMO in doses that had a similar effect on tumor incidence. The close similarity between the effects on cell proliferation and apoptosis of DFMO treatment or transgenic AZ expression is strong evidence that AZ is modulating carcinogenesis through effects on polyamines. The importance of polyamines and ODC in esophageal and stomach carcinogenesis is also supported by studies showing that ODC increases in these tissues of rats responding to regimes that cause tumors (48 , 49) . Similarly, transgenic rats with human c-Ha-ras are highly susceptible to NMBA induction of esophageal tumors (50) , and ODC is a downstream target of ras (17) .

Two factors contribute to the cancer protective effect of AZ. Our findings clearly demonstrate that overexpression of AZ both stimulates apoptosis and inhibits ZD-induced cell proliferation, a condition known to promote forestomach carcinogenesis in ZD mice (40 , 41) . The antiproliferative effects of blocking increases in polyamine content have been documented extensively in cell culture and in vivo (2 , 51) . The ability of cancer chemopreventive agents including DFMO to cause reductions in the proliferative index is a key factor in the current evaluations of these agents in Phase II/III trials (7 , 52, 53, 54) .

The stimulation of apoptosis by AZ or by DFMO, which is shown clearly in the results of Figs. 5Citation and 6Citation , has been less widely recognized than the effects on proliferation, because polyamine levels can have biphasic effects both inhibiting and increasing apoptosis (see Refs. 55 , 56 ). However, it is consistent with results of DFMO treatment in the ZD rat esophagus (43) and of human gastric tumors growing in nude mice (57) . Recent studies have shown that polyamine depletion triggers the mitochondrial-mediated cell death pathway (58) .

More than 50% of human cancers including many esophageal squamous cell carcinomas exhibit alterations that cause a loss of activity of the p53 tumor suppressor protein. Mutations in p53 also occur frequently in rodent esophageal tumors induced by NMBA (59) . Recent studies using p53-deficient mice have shown that the combination of ZD with loss of p53 leads to a large increase in the rate of cell proliferation, a decrease in apoptosis, and the very rapid development of forestomach and esophageal tumors (41) . Our studies on forestomach reported here and in the skin (29 , 30) show that AZ has opposite effects to the loss of p53 and suggest that AZ may be a tumor suppressor gene. Several other findings support this possibility. The content of AZ mRNA is reduced in malignant oral keratinocytes, and AZ expression reversed their malignant phenotype (60) . Expression of AZ blocked tumor formation by H-ras-transfected 3T3 cells in nude mice (61) . AZ-mediated effects on cell proliferation have been documented by several groups (60, 61, 62, 63) . Therefore, additional study of the potential role of AZ as a tumor suppressor gene is warranted. Because of the unique regulation of AZ synthesis in which translational frameshifting is needed for production of the protein, the levels of AZ may not correlate with the mRNA content, and measurement of the active protein content will be required for such studies.

DFMO is currently in clinical trials to prevent cancer in high-risk groups (9 , 64 , 65) . The success of the transgenic AZ approach may be because of the ability of AZ to augment a modest reduction of ODC along with a blockage of the uptake of exogenous polyamines. Therefore, an improved approach might be to combine low doses of DFMO, which are tolerated well, with treatment with an inhibitor of polyamine transport (66 , 67) . Another possibility would be to test inducers of AZ as chemopreventive agents. Several polyamine analogues including some that are in clinical trials as antitumor agents are able to induce AZ (63) . Combination therapy has much promise for cancer prevention, and significant effects in reducing esophageal and stomach cancer has been observed in rodent models with phenethylisothiocyanate, piroxicam, curcumin, and resveratrol (68, 69, 70) . The combinations of these agents with induction of AZ may also be a useful strategy.


    ACKNOWLEDGMENTS
 
We thank David Super (Medical Media Services, Thomas Jefferson University) for mouse forestomach photography, Vu T. Nguyen for animal maintenance, and Suzie Sass-Kuhn for the polyamine analysis.


    FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by grants CA-18138 from the National Cancer Institute (to A. E. P.) and 99B045-REN from the American Institute for Cancer Research (to L. Y. Y. F.). Back

2 To whom requests for reprints should be addressed, at Department of Cellular and Molecular Physiology, H166, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033. Phone: (717) 531-8152; Fax: (717) 531-5157; E-mail: aep1{at}psu.edu Back

3 The abbreviations used are: ODC, ornithine decarboxylase; AZ, antizyme; ZD, zinc-deficient; NMBA, N-nitrosomethylbenzylamine; K5, keratin 5; Wt, wild-type; ZS, zinc-sufficient; DFMO, {alpha}-difluoromethylornithine; K6, keratin 6; SCJ, squamocolumnar junction between fore- and hindstomach; PCNA, proliferating cell nuclear antigen; TUNEL, terminal deoxynucleotidyltransferase-mediated nick end labeling; LI, labeling index; AI, apoptotic index; DAB, 3,3'-diaminobenzidine tetrahydrochloride. Back

Received 12/16/02. Accepted 5/ 8/03.


    REFERENCES
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Heby O., Persson L. Molecular genetics of polyamine synthesis in eukaryotic cells. TIBS, 15: 153-158, 1990.
  2. Pegg A. E. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res., 48: 759-774, 1988.[Abstract/Free Full Text]
  3. Pendeville H., Carpino N., Marine J. C., Takahashi Y., Muller M., Martial J. A., Cleveland J. L. The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol. Cell. Biol., 21: 6459-6558, 2001.
  4. Nishimura K., Nakatsu F., Kashiwagi K., Ohno H., Saito H., Saito T., Igarashi K. Essential role of S-adenosylmethionine decarboxylase in mouse embryonic development. Genes Cells, 7: 41-47, 2002.[Abstract]
  5. Bachrach U., Wang Y. C., Tabib A. Polyamines: New cues in cellular signal transduction. News Physiol. Sci., 16: 106-110, 2001.[Abstract/Free Full Text]
  6. Marton L. J., Pegg A. E. Polyamines as targets for therapeutic intervention. Annu. Rev. Pharm., 35: 55-91, 1995.
  7. Kelloff G. J., Boone C. W., Steele V. E., Lubet R. A., Doddy L. A., Malone W. F., Hawk E. T., Sigman C. C. New agents for cancer chemoprevention. J. Cell. Biochem., 26(Suppl.): 1-28, 1996.
  8. Casero R. A., Jr., Woster. P. M. Terminally alkylated polyamine analogues as chemotherapeutic agents. J. Med. Chem., 44: 1-26, 2001.[Medline]
  9. Simoneau A. R., Gerner E. W., Phung M., McLaren C. E., Meyskens F. L. {alpha}-Difluoromethylornithine and polyamine levels in the human prostate: results of a phase II trial. J. Natl. Cancer Inst., 93: 57-59, 2001.[Free Full Text]
  10. Doyle K. J., McLaren C. E., Shanks J. E., Galus C. M., Meyskens F. L. Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. Arch. Otolaryngol. Head Neck Surg., 127: 553-558, 2001.[Abstract/Free Full Text]
  11. Clifford A., Morgan D., Yuspa S. H., Peralta Soler A., Gilmour S. Role of ornithine decarboxylase in epidermal tumorigenesis. Cancer Res., 55: 1680-1686, 1995.[Abstract/Free Full Text]
  12. Tabib A., Bachrach U. Role of polyamines in mediating malignant transformation and oncogene expression. Int. J. Biochem. Cell Biol., 31: 1289-1295, 1999.[Medline]
  13. Ravanko K., Järvinen K., Paasinen-Sohns A., Hölttä E. Loss of p27Kip1 from cyclin E/cyclin-dependent kinase (CDK) but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes. Cancer Res., 60: 5244-5253, 2000.[Abstract/Free Full Text]
  14. Geng H., Naylor P. H., Dosescu J., Skunca M., Majumdar A. P. N., Moshier J. A. TGF{alpha} is required for full expression of the transformed growth pheneotype of NIH 3T3 cells overexpressing ornithine decarboxylase. Carcinogenesis (Lond.), 21: 567-572, 2000.[Abstract/Free Full Text]
  15. Packham G., Cleveland J. L. Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol. Cell. Biol., 14: 5741-5747, 1994.[Abstract/Free Full Text]
  16. Hölttä E., Auvinen M., Andersson L. C. Polyamines are essential for cell transformation for pp60v-src: Delination of molecular events relevant for the transformed phenotype. J. Cell Biol., 122: 903-914, 1993.[Abstract/Free Full Text]
  17. Shantz L. M., Pegg A. E. Ornithine decarboxylase induction in transformation by the Raf/MAPK and Rac/Rho signal transduction pathways. Cancer Res., 58: 2748-2753, 1998.[Abstract/Free Full Text]
  18. Hurta R. A. R., Lee J., Voskas D. Transformation by H-ras can result in aberrant regulation of ornithine decarboxylase gene expression by transforming growth factor-ß1. J. Cell. Biochem., 81: 39-55, 2001.[Medline]
  19. Li R-S., Law G. L., Seifert R. A., Romaniuk P. J., Morris D. R. Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1. Exp. Cell Res., 247: 257-266, 1999.[Medline]
  20. Chen Y., Megosh L. C., Gilmour S. K., Sawicki J. A., O’Brien. T. G. K6/ODC transgenic mice as a sensitive model for carincogen identification. Toxicol. Lett., 116: 27-35, 2000.[Medline]
  21. Ahmad N., Gilliam A. C., Katiyar S. K., O’Brien T. G., Mukhtar H. A definitive role of ornithine decarboxylase in photocarcinogenesis. Am. J. Pathol., 159: 885-892, 2001.[Abstract/Free Full Text]
  22. O’Brien T. G., Megosh L. C., Gilliard G., Peralta Soler A. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion. Cancer Res., 57: 2630-2637, 1997.[Abstract/Free Full Text]
  23. Morris D. R., Davis R., Coffino P. A new perspective on ornithine decarboxylase regulation: prevention of polyamine toxicity is the overriding theme. J. Cell. Biochem., 46: 102-105, 1991.[Medline]
  24. Pegg A. E., Shantz L. M., Coleman C. S. Ornithine decarboxylase: structure, function and translational regulation. Biochem. Soc. Transact., 22: 846-852, 1995.
  25. Shantz L. M., Pegg A. E. Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway. Int. J. Biochem. Cell Biol., 31: 107-122, 1999.[Medline]
  26. Ivanov I. P., Matsufuji S., Murakami Y., Gesteland R. F., Atkins J. F. Conservation of polyamine regulation by translational frameshifting from yeast to mammals. EMBO J., 19: 1907-1917, 2000.[Medline]
  27. Coffino P. Regulation of cellular polyamines by antizyme. Nat. Rev. Mol. Cell. Biol., 2: 188-194, 2001.[Medline]
  28. Ivanov I. P., Rohrwasser A., Terreros D. A., Gesteland R. F., Atkins J. F. Discovery of a spermatogenesis stage-specific ornithine decarboxylase antizyme: antizyme 3. Proc. Natl. Acad. Sci. USA, 97: 4808-4813, 2000.[Abstract/Free Full Text]
  29. Feith D. J., Shantz L. M., Pegg A. E. Targeted antizyme expression in the skin of transgenic mice reduces tumor promoter induction of ornithine decarboxylase and decreases sensitivity to chemical carcinogenesis. Cancer Res., 61: 6073-6081, 2001.[Abstract/Free Full Text]
  30. Pegg A. E., Feith D. J., Fong L. Y. Y., Coleman C. S., O’Brien T. G., Shantz L. M. Transgenic mouse models for studies of the role of polyamines in normal, hypertophic and neoplastic growth. Biochem. Soc. Transact., 31: 356-360, 2003.[Medline]
  31. Bol D., Kiguchi K., Beltran L., Rupp T., Moats S., Gimenez-Conti I., Jorcano J., DiGiovanni J. Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter. Mol. Carcinog., 21: 2-12, 1998.[Medline]
  32. He W., Li A. G., Wang D., Han S., Zheng B., Goumans M. J., Ten Dijke P., Wang X. J. Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues. EMBO J., 21: 2580-2590, 2002.[Medline]
  33. Pierce A. M., Schneider-Broussard R., Gimenez-Conti I. B., Russell J. L., Conti C. J., Johnson D. G. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol. Cell. Biol., 19: 6408-6414, 1999.[Abstract/Free Full Text]
  34. Ramirez A., Bravo A., Jorcano J. L., Vidal M. Sequences 5' of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation, 58: 53-64, 1994.[Medline]
  35. DiGiovanni J., Kiguchi K., Frijhoff A., Wilker E., Bol D. K., Beltran L., Moats S., Ramirez A., Jorcano J., Conti C. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc. Natl. Acad. Sci. USA, 97: 3455-3460, 2000.[Abstract/Free Full Text]
  36. Fong L. Y. Y., Li J. X., Farber J., Magee P. N. Cell Proliferation and esophageal tumorigenesis in the zinc deficient rat. Carcinogenesis (Lond.), 17: 1841-1848, 1996.[Abstract/Free Full Text]
  37. Fong L. Y. Y., Sivak A., Newberne P. M. Zinc deficiency and methylbenzylnitrosamine induced esophageal cancer in rats. J. Natl. Cancer Inst., 61: 145-150, 1978.
  38. Stinson S. F., Squire R. A., Sporn M. B. Pathology of esophageal neoplasms and associated proliferative lesions induced in rats by N-methyl-N-benzylnitrosamine. J. Natl. Cancer Inst., 61: 1471-1475, 1978.
  39. Lu S. H., Montesano R., Zhang M. S., Feng L., Luo F. J., Chui S. X., Umbenhauer D., Saffhill R., Rajewsky M. F. Relevance of N-nitrosamines to esophageal cancer in China. J. Cell. Physiol., 4(Suppl.): 51-58, 1986.
  40. Fong L. Y. Y., Magee P. N. Dietary zinc deficiency enhances esophageal cell proliferation and N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumor incidence in C57BL/6 mouse. Cancer Lett., 143: 63-69, 1999.[Medline]
  41. Fong L. Y. Y., Ishii H., Nguyen V. T., Vecchione A., Farber J. L., Croce C. M., Huebner K. p53 deficiency accelerates induction and progression of esophageal and forestomach tumors in zinc-deficient mice. Cancer Res., 63: 186-195, 2003.[Abstract/Free Full Text]
  42. Leininger J. R., Jokinen M. P. Tumours of the oral cavity, pharynx, oesophagus and stomach Turusov V. S. Mohr U. eds. . Tumours of the Mouse, Ed. 2 167-193, IARC Lyon, France 1994.
  43. Fong L. Y. Y., Nguyen V. T., Pegg A. E., Magee P. N. {alpha}-Difluoromethylornithine induction of apoptosis: a mechanism which reverses pre-established cell proliferation and cancer initiation in esophageal carcinogenesis in zinc-deficient rats. Cancer Epidemiol. Biomark. Prev., 10: 191-199, 2001.[Abstract/Free Full Text]
  44. Kerr J. F. R. Apoptosis, its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.[Medline]
  45. Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases. INK4 inhibitors and cancer. Biochim. Biophys. Acta, 1602: 73-87, 2002.[Medline]
  46. Fong L. Y. Y., Lau K-M., Huebner K., Magee P. N. Induction of esophageal tumors in zinc deficient rats by single low doses of N-nitrosomethylbenzylamine (NMBA): analysis of cell proliferation, and mutations in H-ras and p53 genes. Carcinogenesis (Lond.), 18: 1477-1484, 1997.[Abstract/Free Full Text]
  47. Lin Y., Martin J., Gruendler C., Farley J., Meng X., Li B. Y., Lechleider R., Huff C., Kim R. H., Grasser W. A., Paralkar V., Wang T. A novel link between the proteasome pathway and the signal transduction pathway of the bone morphogenetic proteins (BMPs). BMC Cell Biol, 3: 15 2002.[Medline]
  48. Daliam A., Savoure N., Ramee M. P., Desrues B., Dazord L., Nicol M. Ornithine decarboxylase basal activity in liver, oesophagus and lung of vitamin A deficient rats, and the effect of retinoic acid. Carcinogenesis (Lond.), 9: 2161-2164, 1988.[Abstract/Free Full Text]
  49. Otani K., Yano Y., Hasuma T., Arakawa T., Kobayashi K., Matsui-Yuasa I., Otani S. Polyamine metabolism of rat gastric mucosa after oral administration of hypertonic sodium chloride solution. Am. J. Physiol., 274: G299-G305, 1998.
  50. Asamoto M., Toriyama-Baba H., Ohnishi T., Naito A., Ota T., Ando A., Ochiya T., Tsuda H. Transgenic rats carrying human c-Ha-ras proto-oncogene are highly susceptible to N-nitrosomethylbenzylamine induction of esophageal tumorigenesis. Jpn. J. Cancer Res., 93: 744-751, 2002.[Medline]
  51. McCann P. P., Pegg A. E. Ornithine decarboxylase as an enzyme target for therapy. Pharmacol. Ther., 54: 195-215, 1992.[Medline]
  52. Steele V. E., Sharma S., Mehta R., Elmore E., Redpath J. L., Rudd C., Bagheri D., Sigman C. C., Kelloff G. J. The use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J. Cell. Biochem., 265: 29-53, 1996.
  53. D’Ambrosio S. M., Gibson-D’Ambrosio R., Milo G. E., Casto B., Kelloff G. J., Steele V. E. Differential response of normal, premaligant, and malignant human oral epithelial cells to growth inhibition by chemopreventive agents. Anticancer Res., 20: 2273-2380, 2000.[Medline]
  54. Elmore E., Stringer D. E., Steele V. E., Gerner E. W., Redpath J. L. Chemoprevention by difluoromethylornithine: correlation of an in vitro human cell assay with human clinical data for biomarker modulation. Anticancer Res., 21: 1163-1165, 2001.[Medline]
  55. Schipper R. G., Penning L. C., Verhofstad A. A. J. Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors?. Cancer Biol, 10: 55-68, 2000.
  56. Stefanelli C., Tantini B., Fattori M., Stanic I., Pignatti C., Clo C., Guarnieri C., Caldarera C. C., Mackintosh C. A., Pegg A. E., Flamigni F. Caspase activation in etoposide-treated fibroblasts is correlated to ERK phosphorylation and both events are blocked by polyamine depletion. FEBS Lett., 527: 223-228, 2002.[Medline]
  57. Takahashi Y., Mai M., Nishioka K. {alpha}-Difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model. Int. J. Cancer, 85: 243-247, 2000.[Medline]
  58. Nitta T., Igarashi K., Yamamoto N. Polyamine depletion induces apoptosis through mitochondria-mediated pathway. Exp. Cell Res., 276: 120-128, 2002.[Medline]
  59. Wang D., Weghorst C. M., Calvert R. J., Stoner G. D. Mutations in the p53 tumor suppressor gene in rat esophageal papillomas induced by N-nitrosomethylbenzylamine. Carcinogenesis (Lond.), 17: 625-630, 1996.[Abstract/Free Full Text]
  60. Tsuji T., Usui S., Aida T., Tachikawa T., Hu G. F., Sasaki A., Matsumura T., Todd R., Wong D. T. W. Induction of epithelial differentiation and DNA demethylation in hamster malignant oral keratinocyte by ornithine decarboxylase antizyme. Oncogene, 20: 24-33, 2001.[Medline]
  61. Iwata S., Sato Y., Asada M., Takagi M., Tsujimoto A., Inaba T., Yamada T. Anti-tumor activity of antizyme which targets the ornithine decarboxylase required for cell growth and transformation. Oncogene, 18: 165-172, 1999.[Medline]
  62. Koike C., Chao D. T., Zetter B. R. Sensitivity to polyamine-induced growth arrest correlated with antizyme induction in prostate carcinoma cells. Cancer Res., 59: 6109-6112, 1999.[Abstract/Free Full Text]
  63. Mitchell J. L., Leyser A., Holtorff M. S., Bates J. S., Frydman B., Valasinas A., Reddy V. K., Marton L. J. Antizyme induction by polyamine analogues as a factor of cell growth inhibition. Biochem. J., 366: 663-671, 2002.[Medline]
  64. Alberts D. S., Dorr R. T., Einspahr J. G., Aickin M., Saboda K., Xu M. J., Peng Y-M., Goldman R., Foote J. A., Warneke J. A., Salasche S., Roe D. J., Bowden G. T. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol. Biomark. Prev., 9: 1281-1286, 2000.[Abstract/Free Full Text]
  65. Carbone P. P., Pirsch J. D., Thomas J. P., Douglas J. A., Verma A. K., Larson P. O., Snow S., Tutsch K. D., Pauk D. Phase I Chemoprevention study of difluoromethylornithine in subjects with organ transplants. Cancer Epidemiol. Biomark. Prev., 10: 657-661, 2001.[Abstract/Free Full Text]
  66. Burns M. R., Carlson C. L., Vanderwerf S. M., Ziemer J. R., Weeks R. S., Cai F., Webb H. W., Graminski G. F. Amino acid/spermine conjugates: polyamine amides as potent spermidine uptake inhibitors. J. Med. Chem., 44: 3632-3644, 2001.[Medline]
  67. Graminski G. F., Carlson C. L., Ziemer J. R., Cai F., Vermeulen N. M., Vanderwerf S. M., Burns M. R. Synthesis of bis-spermine dimers that are potent polyamine transport inhibitors. Bioorg. Chem., 12: 35-40, 2002.
  68. Carlton P. S., Gopalakrishnan R., Gupta R., Liston b. W., Habib S., Morse M. A., Stoner G. D. Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus. Cancer Res., 62: 4376-4382, 2002.[Abstract/Free Full Text]
  69. Ushida J., Sugie S., Kawabata K., Pham Q. V., Tanaka T., Fujii K., Takeuchi T., Ito Y., Mori H. Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Jpn. J. Cancer Res., 91: 893-898, 2002.
  70. Li Z. G., Hong T., Shimada Y., Komoto I., Kawabe A., Ding Y., Kaganoi J., Hashimoto Y., Imamura M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis (Lond.), 23: 1531-1536, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Cancer Res.Home page
K. J. Svensson, J. E. Welch, P. Kucharzewska, P. Bengtson, M. Bjurberg, S. Pahlman, G. B. Ten Dam, L. Persson, and M. Belting
Hypoxia-Mediated Induction of the Polyamine System Provides Opportunities for Tumor Growth Inhibition by Combined Targeting of Vascular Endothelial Growth Factor and Ornithine Decarboxylase
Cancer Res., November 15, 2008; 68(22): 9291 - 9301.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
I. P. Ivanov and J. F. Atkins
Ribosomal frameshifting in decoding antizyme mRNAs from yeast and protists to humans: close to 300 cases reveal remarkable diversity despite underlying conservation
Nucleic Acids Res., March 19, 2007; 35(6): 1842 - 1858.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. J. Lopez-Contreras, C. Lopez-Garcia, C. Jimenez-Cervantes, A. Cremades, and R. Penafiel
Mouse Ornithine Decarboxylase-like Gene Encodes an Antizyme Inhibitor Devoid of Ornithine and Arginine Decarboxylating Activity
J. Biol. Chem., October 13, 2006; 281(41): 30896 - 30906.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. W. Kim, U. Mangold, C. Waghorne, A. Mobascher, L. Shantz, J. Banyard, and B. R. Zetter
Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism
J. Cell Sci., June 15, 2006; 119(12): 2583 - 2591.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. E. Pegg
Regulation of Ornithine Decarboxylase
J. Biol. Chem., May 26, 2006; 281(21): 14529 - 14532.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. J. Feith, S. Origanti, P. L. Shoop, S. Sass-Kuhn, and L. M. Shantz
Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis
Carcinogenesis, May 1, 2006; 27(5): 1090 - 1098.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-G. Liu, L. Zhang, Y. Jiang, D. Chatterjee, C. M. Croce, K. Huebner, and L. Y.Y. Fong
Modulation of Gene Expression in Precancerous Rat Esophagus by Dietary Zinc Deficit and Replenishment
Cancer Res., September 1, 2005; 65(17): 7790 - 7799.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. J. Feith, D. K. Bol, J. M. Carboni, M. J. Lynch, S. Sass-Kuhn, P. L. Shoop, and L. M. Shantz
Induction of Ornithine Decarboxylase Activity Is a Necessary Step for Mitogen-Activated Protein Kinase Kinase-Induced Skin Tumorigenesis
Cancer Res., January 15, 2005; 65(2): 572 - 578.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
L. Y. Y. Fong, L. Zhang, Y. Jiang, and J. L. Farber
Dietary Zinc Modulation of COX-2 Expression and Lingual and Esophageal Carcinogenesis in Rats
J Natl Cancer Inst, January 5, 2005; 97(1): 40 - 50.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A.-T. Vlastos, L. A. West, E. N. Atkinson, I. Boiko, A. Malpica, W. K. Hong, and M. Follen
Results of a Phase II Double-Blinded Randomized Clinical Trial of Difluoromethylornithine for Cervical Intraepithelial Neoplasia Grades 2 to 3
Clin. Cancer Res., January 1, 2005; 11(1): 390 - 396.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. M. Newman, A. Mobascher, U. Mangold, C. Koike, S. Diah, M. Schmidt, D. Finley, and B. R. Zetter
Antizyme Targets Cyclin D1 for Degradation: A NOVEL MECHANISM FOR CELL GROWTH REPRESSION
J. Biol. Chem., October 1, 2004; 279(40): 41504 - 41511.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Y. Y. Fong, R. Mancini, H. Nakagawa, A. K. Rustgi, and K. Huebner
Combined Cyclin D1 Overexpression and Zinc Deficiency Disrupts Cell Cycle and Accelerates Mouse Forestomach Carcinogenesis
Cancer Res., July 15, 2003; 63(14): 4244 - 4252.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fong, L. Y. Y.
Right arrow Articles by Pegg, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fong, L. Y. Y.
Right arrow Articles by Pegg, A. E.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online